Reduced bile duct contractile function in rats with chronic hyperglycemia

Chi-Ming Liu¹, Hui-Chen Su², Yen-Ting Wang¹, Tao-Hsin Tung¹, Pesus Chou³, Yiing-Jeng Chou³, Jorn-Hon Liu¹, Jan-Kan Chen⁴*

¹Cheng-Hsin General Hospital, Taipei, Taiwan, China
²Chi-Mei Medical Center, Tainan, Taiwan, China
³Institute of Public Health, National Yang Ming University, Taipei, Taiwan, China
⁴Department of Physiology, College of Medicine, Chang Gung University, Taipei, Taiwan, China;
*Corresponding Author: jkc508@mail.cgu.edu.tw

Received 27 November 2009; revised 11 January 2010; accepted 3 March 2010.

ABSTRACT

The incidence of gallstone is higher in patients with diabetes mellitus than in general population. It is generally attributed to hypomotility and lowered emptying function of the gallbladder. In this study, we investigate if chronic hyperglycemia is correlated with reduced contractile function of the bile ducts in rat. Hyperglycemic rats were induced by streptozotocin-nicotinamide treatment. Hyperglycemic rats were sacrificed eight months after induction and bile ducts were removed for the subsequent studies. The bile duct contractility of the normal rats is consistently higher than that of the hyperglycemic rats. The contractilities were measured to be 5.5 ± 0.2 mg vs. 4.2 ± 0.1 mg without CCK stimulation, and 5.5 ± 0.3 mg vs. 7.9 ± 0.4 mg with CCK stimulation, respectively for hyperglycemic and normal rats. There was no significant difference in plasma CCK concentration in hyperglycemic rats and normal rats. The expression of CCK-A receptor protein in the bile duct tissue was decreased in hyperglycemic rats compared with that of the normal rats, and it may, at least in part, responsible for a reduced contractility. A reduced bile duct motility may cause bile retention, and may be one of the factors predispose to gallstone formation in type 2 diabetes patients, which is characterized with chronic hyperglycemia.

Keywords: Hyperglycemia; Bile Duct; Contractile

1. INTRODUCTION

Cholelithiasis is one of the most prevalent gastroentero-logic diseases in humans. It is a complex metabolic disorders, and its exact pathogenic mechanisms have not been fully elucidated. Gallstones represent a serious burden for the health care systems: over 10% of Europeans and Americans carry gallbladder stones [1], and the prevalence of gallstone disease seems to be rising as a result of longer life expectancy [2]. Many gallstones are silent, but symptoms and severe complications ensure in around 25% of the cases, necessitating surgical removal of the gallbladder [3]. Mortality rates following cholecystectomy range from less than 0.1% in clinical studies [4] to 0.8% (as documented for all cholecystectomies performed in Germany in 2002) [5]. In the US about 3,000 deaths (0.12% of all deaths) per year are attributed to complications of cholelithiasis and gallbladder disease [6]. Nonsurgical approaches, including gallstone dissolution by ursodeoxycholic acid and extracorporeal shockwave lithotripsy, have increasingly lost their impact on therapy and are performed only for uncomplicated symptomatic cholecystolithiasis in a very small number of selected patients.

Bile formation enables the removal of excess cholesterol, either directly or after catabolism to bile salts, and it is a key function of the liver. Bile is an aqueous solution of lipids, in which bile salts (67% of solutes by weight), phospholipids (22%) and cholesterol (4%) representing the three main lipid species [7]. More than 80% of gallstones consist mainly of cholesterol and are formed within the gallbladder [8]. Three major mechanisms contribute to the formation of cholesterol gallbladder stones: cholesterol supersaturation of bile, gallbladder hypomotility and destabilization of bile by kinetic protein factors. Cholesterol-supersaturated bile contains more cholesterol than can be solubilized by mixed micelles (cholesterol saturation index > 1). It contains multilamellar vesicles (liquid crystals), whose
fusion and aggregation precede the formation of solid cholesterol crystals. As illustrated in the classic triangular phase diagram, solid crystals occur in bile at high relative bile salt and low phospholipids concentrations and at cholesterol: phospholipids ratios > 1 [7]. An excess of biliary cholesterol in relation to bile salts and phospholipids can result from hypersecretion of cholesterol, or from hyposecretion of bile salts or phospholipids. Cholesterol hypersecretion is the most common cause of supersaturation [8]. It might be caused by increased hepatic uptake or synthesis of cholesterol, decreased hepatic synthesis of bile salts, or decreased hepatic synthesis of cholesteryl esters for incorporation in VLDL. Accordingly, any enzyme, transporter or regulator involved in hepatic cholesterol metabolism could potentially affect the formation of cholesterol gallstones [9]. In humans, most gallstone cholesterol is of dietary origin, consistent with the observation that hepatic biosynthesis contributes less than 20% of the biliary cholesterol [2]. The hepatic uptake of cholesterol is mediated by the scavenger receptor B1 for HDL, which contributes most of the biliary cholesterol under physiological conditions. The inverse correlation between serum HDL levels and gallstones suggests that cholesterol cholelithiasis is associated with an induced reverse cholesterol transport and hepatic catabolism of HDL [2]. The rate-limiting enzymes of hepatic cholesterol and bile salt synthesis are 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cholesterol 7α-hydroxylase, respectively. These enzymes are regulated by the sterol-regulatory-element-binding protein (SRBP) and nuclear receptor signaling pathways [10,11]. Stasis of bile in the gallbladder favours stone formation, as indicated by stone formation during pregnancy, rapid weight loss or total parenteral nutrition. Postprandial gallbladder volumes are increased and gallbladder emptying in response to cholecystokinin (CCK) is impaired in patients with gallstones [8], probably as a result of absorption of cholesterol from supersaturated bile by gallbladder wall. Excess cholesterol in smooth-muscle cells stiffens sarcolemmal membranes and decouples the G-protein-mediated signal transduction of the CCK, thereby paralyzing gallbladder contractile function [12].

Among the patients in China, about 10% of them also bear gallstones. The impaired emptying function owing to hypomotility of the gallbladder is considered an important factor for the development of cholelithiasis [13-17]. Because of hypomotility and lowered emptying function, the incidence of gallstone is higher in patients with diabetes mellitus than in general population, however, its underlying mechanism has not been well understood.

Gallbladder mortality is regulated by cholinergic and gastrointestinal hormone [18,19]. Postprandial gallbladder emptying is triggered mainly by plasma CCK from the small intestine. CCK interacts with CCK receptor-1 (CCK-R) in gallbladder smooth muscle cells, which in turn elicits the contraction of gallbladder by the activation of post-membrane signaling pathway [20]. We hypothesize that abnormal gallbladder contraction in response to CCK, may play an important role in the development of cholesterol gallstone in hyperglycemic patient. The purpose of this study was to examine if there are differences in gallbladder motor function, plasma CCK concentration, and the CCK-R activity in response to CCK in hyperglycemic and normal rats.

2. MATERIALS AND METHODS

2.1. Animals

Male SD rats, age 8-10 week, obtained from the National Laboratory Animal Center, Taiwan, were used for the study. Streptozotosine (STZ), which selectively destroys the pancreatic β-cells that secrete insulin, was used to induce insulin dependent DM, and nicotinamide was used to attenuate STZ effect to induced insulin-deficient diabetic rats [21]. STZ-nicotinamide DM rats were induced in overnight fasted animals by a single intravenous injection of STZ (60 mg/kg body weight), and nicotinamide (120 mg/kg body weight) (Sigma Chemical Co., St Louis, MO) was administered intraperitoneally 15 min after STZ. Combined administration of STZ and nicotinamide leads to the development of a diabetic syndrome, which is characterized by moderate and stable hyperglycemia and reduced pancreatic insulin stores [22].

Hyperglycemia was confirmed by elevated plasma glucose levels, measured on days 3 and 7 after drug injection. STZ-nicotinamide treated rats exhibited a fasting plasma glucose concentration of 13.4 ± 0.8 mmol/L and a plasma insulin level of 95.0 ± 0.2 pmol/L (n = 24). In contrast, the fasting plasma glucose and insulin levels of the normal rats were 4.8 ± 0.05 mmol/L and 16.8 ± 4.8 pmol/L, respectively (n = 24). All studies were carried out with animals two weeks after the induction of diabetes. Blood samples were taken from overnight fasted rats at 0, 2, 4, 6 and 8 months after the confirmation of hyperglycemia.

2.2. Bile Duct Contractile Response

Bile ducts were isolated from hyperglycemic rats and normal rats, respectively, and placed in Kreb’s solution containing (in mmol/L) 118.4 NaCl, 25 NaHCO3, 11.66 glucose, 4.75 KCl, 1.18 MgSO4·7H2O, 2.5 CaCl2·2H2O, 1.19 KH2PO4, 0.02 EDTA. The solution was maintained...
at pH 7.4 and continuously bubbled with 95%O2-5%CO2.
Bile ducts were carefully mounted on the isometric force
transducer in the organ chamber (95%O2-5%CO2, at
37°C), and were equilibrated for 90 minutes in an organ
bath with a resting tension of 1.8 mg. CCK (from 10⁻²-
10⁻⁵ M) was used to induce bile duct contraction.

2.3. Determination of Plasma CCK
Concentration

Animals were fasted overnight and anesthetized by pent-
tobarbital (30 mg kg⁻¹ body weight, i.p.). Blood samples
(0.1 mL) were collected from femoral vein using a chilled syringe that contained 10 IU heparin. Plasma CCK levels were measured by enzyme immunoassay of 50 μL aliquots of plasma with a CCK octapeptide rat
ELISA kit (Harbor Boulevard, Belmont, California). The
immunoplate in this kit is pre-coated with secondary antibody and the nonspecific binding sites are blocked.
The secondary antibody binds to the Fc fragment of the
primary antibody (peptide antibody) whose Fab frag-
ment will be competitively bound by both biotinylated
peptide and peptide standard or targeted peptide in sam-
ples. The biotinylated peptide is able to interact with
streptavidin-horseradish peroxidase (SA-HRP) which
catalyzes the conversion of 3,3',5,5'-tetramethylbenzi-
dine (TMB) to produce a blue colored solution. The re-
cation was stopped by adding acid and the reaction solu-
tion turned yellow and was read spectrophotometrically.

2.4. Determination of Plasma Glucose

Animals were fasted overnight and anesthetized by pen-
tobarbital (30 mg kg⁻¹ body weight, i.p.). Blood samples
(0.1 mL) were collected from femoral vein using a chilled syringe that contained 10 IU heparin. The sam-
ples were centrifuged at 13,000 rpm for 3 min, and ali-
quot (0.1 mL) of plasma was added to 1.5 ml of a Glucose
Kit Reagent (Biosystems S.A., Barcelona, Spain) and
incubated at 37°C in a water bath (Yamato-BT-25, Tokyo,
Japan) for 10 min. Plasma glucose was determined by a
glucose analyzer (Quik-Lab, Ames, Miles Inc., Elkhart,
IN).

2.5. Determination of Plasma Insulin

Plasma insulin levels were measured by enzyme immu-
noassay of 25 μL aliquots of plasma with a Rat Insulin
ELISA kit (Mercodia, Uppsala, Sweden). During incu-
bation, insulin in the sample reacted with peroxidase-conjugated anti-insulin antibodies which were bound to
the plastic surface of the microtitration well. The bound conjugate was detected by reaction with 3,3',5,5'-tetra-
methylbenzidine. The reaction was stopped by adding
acid to give a colorimetric endpoint that was read spec-
trophotometrically.

2.6. Western Blot Analysis

Bile ducts were homogenized by mechanical homogeni-
ization using a glass/Teflon homogenizer. Protein content
was determined using the BCA™ protein assay kit
(Rockford, USA). A total of 50 μg of tissue protein was
fractionated on 10% sodium dodecyl sulfate/polyacryla-
mide gel electrophoresis (SDS/PAGE). Following trans-
fer, the membrane was washed with phosphate-buffer
saline (PBS) and blocked for 1 h at room temperature
with 5% (w/v) skimmed milk in PBS. Blots were then
incubated overnight at 4°C with the polyclonal antibod-
ies against rat bile duct CCK-A or CCK-B (both at
1:1000) (abcam Littleton, CO). β-actin was also blotted
with mouse monoclonal antibody (1:1000) against β-actin
and served as internal reference. After removing the
primary antibody, the blots were extensively washed
with PBS/Tween 20, and incubated for 1 h at room tem-
perature with the appropriate peroxidase-conjugated
secondary antibody. Following removal of the secondary antibody, blots were washed as described and developed
by autoradiography using the ELC-Western blotting sys-
tem (Amersham Corp.). Densities of the obtained immu-
unoblots at 50 KDa for CCK-B, 48 KDa for CCK-A and
42 KDa for β-actin were quantified using a laser densi-
tometer.

2.7. Statistical Analysis

Data are expressed as mean ± SEM (standard error of the
mean). Repeated measures of analysis of variance
(ANOVA) were used to analyze the changes in plasma
glucose and other parameters. The Dunnett range of post
hoc comparisons was used to determine the source of
significant differences where appropriate. A p value of
0.05 or less was considered as significant.

3. RESULTS

3.1. Measurement of the Plasma Glucose
and Insulin Levels

Plasma glucose and insulin levels were measured from
blood samples taken from overnight fasted rats. The
blood glucose concentrations measured at 0, 2, 4, 6 and
8 months after confirmation of the hyperglycemia were
13.4 ± 0.8, 14.4 ± 0.6, 15.6 ± 0.2, 16.2 ± 0.1, 16.6 ± 0.2
mmol/L, respectively (Figure 1). The plasma insulin
concentrations measured at the same time intervals after
confirmation of hyperglycemia were 95.0 ± 0.2, 99.5 ±
0.4, 115.2 ± 0.3, 125.6 ± 0.6 and 128.4 ± 0.8 pmol/L,
respectively (Figure 1). During the same period of time,
the plasma glucose and insulin levels of the normal rats
were 4.8 ± 0.5 mmol/L and 168.5 ± 4.8 pmol/L, respec-
tively (n = 24).
3.2. Measurement of the Plasma CCK Levels

No significant difference in plasma CCK levels between normal and hyperglycemic rats were observed. In the fed normal and fed hyperglycemic rats, the plasma CCK levels were ranged from 0.70 ± 0.05 to 0.79 ± 0.04 ng/ml, and 0.74 ± 0.06 to 0.78 ± 0.04 ng/ml, respectively (Figure 2(a)). In overnight fasted normal and hyperglycemic rats, the plasma CCK levels were ranged from 0.41 ± 0.06 to 0.43 ± 0.04 ng/ml, and 0.42 ± 0.04 to 0.44 ± 0.05 ng/ml, respectively (Figure 2(b)).

3.3. Effect of CCK on Bile Duct Contraction

Bile duct contraction in response to graded doses of CCK was measured in an organ bath as described. Bile duct rings obtained from normal rats contracted in response to CCK in a dose dependent manner. At 10^{-5} M CCK, a 20% increase of the ring tension was observed (Figure 3).

Bile duct rings prepared form hyperglycemic rats at 8 months after confirmation of hyperglycemia symptom exhibited lower contractile tension under the same CCK dose range (Figure 3). The contractile response to CCK was somewhat dose responsive, however, at the highest CCK concentration (10^{-5} M) used, the tension generated was still lower than that of the normal without CCK stimulation.

3.4. Expression of CCK Receptor in Bile Duct

Total bile duct tissue lysates were prepared from normal and hyperglycemic rats. Proteins were fractionated on a 10% SDS-PAGE, transferred to cellulose nitrate membrane and blotted for CCK-A receptor. Figure 4 is a representative blot shown that the protein content of the CCK-A receptor in hyperglycemic rats was reduced by about 50% compared to that of the normal rats.

4. DISCUSSION

Epidemiological studies have shown that obesity, hyperinsulinemia, and diabetes are important risk factors for the development of the gallstones [23,24]. Hyperinsulinemia, or insulin resistance, and obesity are among the metabolic syndrome cluster, and people with metabolic syndrome have been shown to predispose to diabetes, cardiovascular disease, hypertension and gallstone disease [25]. Metabolic disorders may affect the biochemical characteristics, especially the lipid composition of the
bile. In fact, cholesterol supersaturation or an increase cholesterol to phospholipids ratio has been suggested to be one of the determinants for cholesterol gallstone formation [26]. One other possible influencing factor is the contractile function of the gallbladder. The major hormonal regulator of gallbladder contraction in the intestinal phase of digestive function is CCK [27,28]. Reduced gallbladder contraction function due to defect in CCK signaling has been shown to impair gallbladder emptying and enhance gallstone formation [29]. From a recent study we know, gallbladder dysmotility may have accelerated sludge and gallstone formation in male and female CCK-1(A) receptor-deficient mice, but its contribution was limited [30]. Since diabetes patients, which are characterized by chronic hyperglycemia have been reported to have a higher incidence of gallbladder stone disease, we therefore, sought to examine the possible effects of the hyperglycemia on the gallbladder contractile function in response to CCK in rats.

We found that bile duct contractility of the chronically hyperglycemia rats with and without CCK stimulation was consistently lower that of the normal rats. Further examination by Western blotting showed that the expression of CCK-A receptor protein in the bile duct of the hyperglycemic rats was reduced by 50% compared with that of the normal rats. It is therefore concluded that reduced bile duct response to CCK contractile stimulation in hyperglycemic, and perhaps, diabetic rats is due, at least in part, to a reduced expression of CCK-A receptor. Interestingly, the plasma CCK contents of the normal and hyperglycemic rats were not significantly differed. Thus, the reduced bile duct contractility may be one of the important influencing factors of the high co-incidence of gallbladder stone disease and diabetes.

REFERENCES


